As potential therapies for FSHD, multiple groups are developing technologies to inhibit the function or expression of DUX4-FL (e.g. Bosnakovski et al., 2019; Bouwman et al., 2021; Das and Chadwick, 2021; Himeda et al., 2020; Lim et al., 2020, 2021; Lu-Nguyen et al., 2021; Mariot et al., 2020; Mellion et al., 2021; Oliva et al., 2019; Rashnonejad et al., 2020; Šikrová et al., 2021). This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.